421 related articles for article (PubMed ID: 18249193)
1. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
Massart C; Gibassier J; Oger J; Le Page E; Edan G
Clin Chim Acta; 2007 Feb; 377(1-2):185-91. PubMed ID: 17123498
[TBL] [Abstract][Full Text] [Related]
3. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
5. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K;
Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
[TBL] [Abstract][Full Text] [Related]
7. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
Vartanian T; Sölberg Sørensen P; Rice G
J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of interferon beta: differences among products.
Bertolotto A; Deisenhammer F; Gallo P; Sölberg Sørensen P
J Neurol; 2004 Jun; 251 Suppl 2():II15-II24. PubMed ID: 15264108
[TBL] [Abstract][Full Text] [Related]
9. Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera.
Prince HE; Lapé-Nixon M; Audette C; Van Horn K
J Neuroimmunol; 2007 Oct; 190(1-2):165-9. PubMed ID: 17889376
[TBL] [Abstract][Full Text] [Related]
10. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.
Lam R; Farrell R; Aziz T; Gibbs E; Giovannoni G; Grossberg S; Oger J
J Immunol Methods; 2008 Jul; 336(2):113-8. PubMed ID: 18511063
[TBL] [Abstract][Full Text] [Related]
11. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
Perini P; Calabrese M; Biasi G; Gallo P
J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
[TBL] [Abstract][Full Text] [Related]
13. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
McKay F; Schibeci S; Heard R; Stewart G; Booth D
J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
[TBL] [Abstract][Full Text] [Related]
14. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.
Sominanda A; Rot U; Suoniemi M; Deisenhammer F; Hillert J; Fogdell-Hahn A
Mult Scler; 2007 Mar; 13(2):208-14. PubMed ID: 17439886
[TBL] [Abstract][Full Text] [Related]
15. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K
Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
[TBL] [Abstract][Full Text] [Related]
16. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
Hesse D; Sellebjerg F; Sorensen PS
Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
[TBL] [Abstract][Full Text] [Related]
17. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
Hegen H; Schleiser M; Gneiss C; Di Pauli F; Ehling R; Kuenz B; Lutterotti A; Berger T; Deisenhammer F
Mult Scler; 2012 May; 18(5):610-5. PubMed ID: 22013146
[TBL] [Abstract][Full Text] [Related]
18. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
Hartung HP; Freedman MS; Polman CH; Edan G; Kappos L; Miller DH; Montalbán X; Barkhof F; Petkau J; White R; Sahajpal V; Knappertz V; Beckmann K; Lanius V; Sandbrink R; Pohl C;
Neurology; 2011 Aug; 77(9):835-43. PubMed ID: 21849647
[TBL] [Abstract][Full Text] [Related]
19. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
[TBL] [Abstract][Full Text] [Related]
20. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
Bertolotto A; Malucchi S; Milano E; Castello A; Capobianco M; Mutani R
Immunopharmacology; 2000 Jul; 48(2):95-100. PubMed ID: 10936507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]